New Data From Upsher-Smith's Epilepsy Portfolio To Be...
Upsher-Smith, a fully integrated pharmaceutical company committed to the development of new treatments for diseases of the central nervous system , will be sponsoring 13 , is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.
Acute myopia and angle closure glaucoma from topiramate in a...
A case is reported of acute bilateral myopia and angle closure glaucoma in a 7-year-old patient from topiramate toxicity.
Topamax Approval for Migraines Expanded to Younger Users
MONDAY March 31, 2014, 2014 -- U.S. Food and Drug Administration approval of the drug Topamax to prevent migraine headaches has been expanded to include adolescents 12 years to 17 years, the agency said Friday.
Topamex approved to manage migraines in teens
Topomax , first drug to treat migrainesfor kids12-17 FDA approval of a drug for migraine prevention in this age group.
The News Journal
FDA approves Topamax for migraine prevention in adolescents
The U.S. Food and Drug Administration approved Topamax on Friday for the prevention of migraine headaches in adolescents ages 12 to 17, the agency announced.
FDA Ok's Janssen Pharmaceutical Inc. 's Topamax For Migraine Prevention In Adolescents
March 28, 2014 -- Today, the U.S. Food and Drug Administration approved Topamax for prevention of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group.